Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 14/20 | 0.47 |
| ▸ | APOB | P04114 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664562 | 0.92 | HTR2A (0.44) | MTTPAPOBSMN1; SMN2CREBBPLMNA | |
| SCHEMBL6803526 | 0.87 | MTTP (0.49) | MTTPAPOBKDM4EGAASMO | |
| SCHEMBL6805396 | 0.87 | SMO (0.47) | MTTPAPOBKDM4EGAASMN1; SMN2 | |
| SCHEMBL6799386 | 0.84 | SMO (0.55) | MTTPAPOBKDM4EGAASMO | |
| SCHEMBL6804769 | 0.81 | MTTP (0.62) | MTTPAPOBKDM4EGAASMN1; SMN2 | |
| SCHEMBL6805922 | 0.80 | RIPK1 (0.41) | MTTPAPOBKDM4ESMN1; SMN2SMO | |
| SCHEMBL6666513 | 0.79 | MTTP (0.40) | MTTPAPOBSMN1; SMN2SMOLMNA | |
| SCHEMBL6640334 | 0.79 | HTR2A (0.47) | MTTPAPOBCREBBPLMNAMAPT | |
| SCHEMBL6804557 | 0.79 | SMO (0.47) | MTTPAPOBKDM4EGAASMN1; SMN2 | |
| SCHEMBL6804990 | 0.78 | MAPT (0.44) | SMN1; SMN2SMOCREBBPLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | MTTP 108/4885APOB 1/4885KDM4E 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.